RxDoctor Payments Data

Michael Layfield, PA

Medical · Aurora, CONPI 1124157250

Payments from drug & device makers

$6,797in general payments, 2019–2025

Across 341 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$860
  • Gilead$784
  • Johnson & Johnson$741
  • Sanofi$432
  • Pfizer$372
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,67798%
  • Education$1202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,797 in reported general payments places this provider in the 90th percentile of 766 medical providers in Colorado.

See all medical providers in Colorado

Medicare billing

Part B allowed, 2024
$31,686
Medicare patients
201
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab33$875,656
SimponiGolimumab12$84,629
CreonLipase/Protease/Amylase25$77,540
Mesalamine41$25,004
LinzessLinaclotide31$24,064
ViberziEluxadoline12$18,684
TrulancePlecanatide13$8,974
Mesalamine ErMesalamine12$6,280
Ursodiol19$5,755
Erythromycin Ethylsuccinate13$1,853
Omeprazole117$1,485
Azathioprine18$988
Pantoprazole Sodium86$882
Sulfasalazine23$766
Lansoprazole36$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Simponi$741$960,28645 claims
AbbVieCreon, Linzess, Viberzi$1,390$120,28768 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$353$8,97413 claims
SandozLansoprazole$17$65936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 766 medical providers in Colorado.

Other medical in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →